DNAiTECH

Executive Summary

DNAiTECH is a New Zealand-based private company specializing in genetic testing and genomics services for research, diagnostics, and personalized medicine. Founded in 2016, the company has built a platform that integrates advanced genomic analysis with clinical applications, aiming to accelerate precision medicine adoption in underserved markets. With a lean team of 10-50 employees, DNAiTECH focuses on cost-effective, scalable solutions for genetic screening, pharmacogenomics, and rare disease diagnostics. The company's platform-stage positioning suggests a mature technology ready for commercialization, though limited public information on funding and valuation indicates a bootstrapped or early-stage venture. DNAiTECH's strategic location in Christchurch leverages New Zealand's strong biomedical research ecosystem and offers potential for regional expansion into Asia-Pacific. Key challenges include competing against larger genomics players and navigating regulatory pathways for diagnostic tests.

Upcoming Catalysts (preview)

• Q3 2026Launch of new population-specific genomic panel60% success
• Q4 2026Partnership with major research institution or hospital network50% success
• TBDRegulatory clearance for a diagnostic test in New Zealand or Australia40% success